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242 The Journal of Thoracic and Cardbjective: In an international, prospective, observational study, we contrasted
dverse vascular outcomes among four countries and then assessed practice pattern
ifferences that may have contributed to these outcomes.
ethods: A total of 5065 patients undergoing coronary artery bypass graft surgery
ere analyzed at 70 international medical centers, and from this pool, 3180 patients
rom the 4 highest enrolling countries were selected. Fatal and nonfatal postoper-
tive ischemic complications related to the heart, brain, kidney, and gastrointestinal
ract were assessed by blinded investigators.
esults: In-hospital mortality was 1.5% (9/619) in the United Kingdom, 2.0% (9/444)
n Canada, 2.7% (34/1283) in the United States, and 3.8% (32/834) in Germany (P 
03). The rates of the composite outcome (morbidity and mortality) were 12% in the
nited Kingdom, 16% in Canada, 18% in the United States, and 24% in Germany (P
001). After adjustment for difference in case-mix (using the European System for
ardiac Operative Risk Evaluation) and practice, country was not an independent
redictor for mortality. However, there was an independent effect of country on
omposite outcome. The practices that were associated with adverse outcomes were the
ntraoperative use of aprotinin, intraoperative transfusion of fresh-frozen plasma or
latelets, lack of use of early postoperative aspirin, and use of postoperative heparin.
onclusions: Significant between-country differences in perioperative outcome
xist and appear to be related to hematologic practices, including administration of
ntifibrinolytics, fresh-frozen plasma, platelets, heparin, and aspirin. Understanding
he mechanisms for these observations and selection of practices associated with
mproved outcomes may result in significant patient benefit.
oronary artery bypass graft (CABG) surgery was introduced approximately
50 years ago and is now performed in 1 million patients at a cost exceeding
$20 billion annually. As a technically complex procedure that is performed
n high-risk patients, it has been scrutinized closely, resulting in substantial stan-
ardization of surgical, anesthetic, and postoperative care. 1-5 Consequently, one would
xpect that case-mix adjusted cardiovascular mortality and morbidity would be
imilar among high-volume centers, despite national differences in health care
ystems and reimbursement practices.6-8 However, there are few, if any, compre-
ensive, international data sets that allow comparison of the effects of country-
pecific, system-associated factors, such as length of stay, time from diagnosis to
urgery, and variations in the pharmacologic management of hemostasis on mor-
idity and mortality, although these factors vary markedly depending on where
ABG surgery is performed.8-13
iovascular Surgery ● May 2007
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A
CDThe primary aim of this analysis was to determine and
ontrast the adverse vascular outcomes that occurred after
ABG surgery among 4 countries; our hypothesis was that
ascular outcomes differed among countries. Our secondary
ypothesis was that practice pattern differences existed and
ccounted for between-country differences in outcome. The
arget population was patients undergoing elective CABG
urgery (primary or repeat) or combined CABG-valve sur-
ery (replacement or repair) among institutions of 4 coun-
ries, the United States, Canada, the United Kingdom, and
ermany. Patients were randomly sampled by center, and a
omprehensive set of individual perioperative data were col-
ected, to allow definition of practice by center and by country.
aterials and Methods
nrollment in the Multicenter Study of Perioperative Ischemia
esearch Group EPI II Study began in November 1996, and the
n-hospital phase ended in June 2000. A total of 5436 patients
cheduled for CABG surgery were enrolled in 72 medical institu-
ions among 17 countries (4 continents). Details of the EPI II study
ave been described.14 Specifically, at each institution, after insti-
utional review board approval, 100 patients were to be enrolled
rospectively according to a systematic sampling scheme. To be
ligible for enrollment, the patient had to be scheduled to undergo
ABG using cardiopulmonary bypass, had to complete the preop-
rative interview, had to be at least 18 years old, could not be
nrolled in another study or clinical trial, and had to give written
nformed consent.
linical Care
linical decisions were not controlled by the study protocol, and
ll patients qualifying for enrollment within the prespecified en-
ollment period were entered. Of the 5436 patients enrolled, 371
ere excluded from the analysis for the following reasons: with-
rawal from the study (32 patients), death before surgery (2
atients), cancellation or rescheduling of the surgery (97 patients),
hange in procedure (132 patients), incomplete data (97 patients),
r inadvertent enrollment in another study (11 patients).
tudy Data
or our comparison, we chose the 4 highest enrolling countries to
btain the largest and most homogeneous samples of patients
ndergoing elective CABG surgery. All surgery in these countries
as performed at university or university-affiliated teaching hospitals.
he distribution of the patients was as follows: United States (29
enters; n  1283); Germany (9 centers; n  834); United Kingdom
7 centers; n  619); and Canada (8 centers; n  444).
For each enrolled patient, more than 7500 fields of data were
Abbreviations and Acronyms
CABG  coronary artery bypass graft
EuroSCORE European System for Cardiac
Operative Risk Evaluationollected, including demographic, historical, clinical, laboratory, m
The Journal of Thoraciclectrocardiographic, special testing, resource use, and adverse
utcome data. Independent investigators coded all medications
eceived throughout hospitalization from admission to discharge or
ntil death. All data fields for each patient were examined centrally
or completeness and accuracy, with all changes documented be-
ore formal in-hospital database closure on October 15, 2001.
easurement of Outcomes
ll outcomes were prespecified by protocol and diagnosed by
ndependent and blinded investigators. Fatal and nonfatal out-
omes were classified as cardiac (myocardial infarction, heart
ailure), cerebral (stroke, encephalopathy), renal (dysfunction, fail-
re), gastrointestinal (ischemia, infarction), or other adverse event
omplications.14 The diagnosis of myocardial infarction required15
he development of new Q waves (as defined by Minnesota Code
-1-1 up to 1-2-7), new persistent ST-segment or T-wave changes
Minnesota Code 9-2, 4-1, 4-2, 5-1, or 5-2) associated with an
levation of creatine kinase-myocardial band isoenzyme values, or
utopsy evidence of acute myocardial infarction. The diagnosis of
eart failure required the use of a ventricular assist device, the use
f continuous inotropic support for at least 24 hours, or autopsy
erification of heart failure. Cerebral outcomes were classified16 as
linically diagnosed stroke or encephalopathy, or computed to-
ography, magnetic resonance imaging, or autopsy evidence of a
ocal or global lesion. Renal dysfunction was defined17 as a serum
reatinine level of 2.00 mg/dL or greater accompanied by a 0.7
g/dL or greater increase over baseline; renal failure was defined
s dysfunction requiring dialysis or autopsy verification of renal
ailure. Gastrointestinal ischemia18 was defined as abdominal pain
ikely associated with bowel ischemia; gastrointestinal infarction
as defined by bowel resection or evidence of intestinal infarction
n autopsy. In addition, we defined a composite outcome consist-
ng of mortality and/or any of the morbidities: myocardial infarc-
ion, congestive heart failure, stroke, encephalopathy, renal dys-
unction, renal failure, and gastrointestinal ischemia/infarction.
tatistical Analysis
he prevalence of clinical characteristics and the incidence of
ndividual adverse events comprising the composite outcome
death, myocardial infarction, congestive heart failure, stroke, en-
ephalopathy, renal dysfunction, renal failure, or gastrointestinal
schemia/infarction) among the 4 countries were compared using
he chi-square test. Continuous variables (eg, time to surgery and
ength of hospital stay) were compared using nonparametric tests.
The European System for Cardiac Operative Risk Evaluation
EuroSCORE)19 (one of the most common risk stratification sys-
ems for cardiac surgical patients) and other potential risk factors
or adverse outcomes were investigated first using univariate lo-
istic regression analysis. All risk factors statistically significant at
less than .20 in univariate analysis were then entered into a
ultivariate logistic regression model. Stepwise logistic regression
as performed, with variables retained that were significant at a
-tailed nominal P value of less than .05. To investigate the
ifferences among countries, adjusting for their differences in risk
rofile, separate risk models were developed for mortality, mor-
idity, early morbidity (within 48 hours postsurgery), and late
orbidity (after 48 hours postsurgery). All statistical analyses
and Cardiovascular Surgery ● Volume 133, Number 5 1243
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A
CDere performed with SAS Version 8.12 software (SAS Institute,
ary, NC).
The Ischemia Research and Education Foundation provided all
unding for execution of the study, collection of the data, and
nalysis and publication of the findings.
esults
atients typically had chronic and acute manifestations of
ascular disease (Table 1). U.S. patients had the highest
revalence of body mass index greater than 30 kg/m2,
iabetes, unstable angina, prior CABG, left main coronary
rtery disease, ejection fraction less than 44%, and non-
aucasian ethnicity. U.K. patients had a higher prevalence
f heart failure and acute smoking cessation but were the
ABLE 1. Baseline demographic and medical characterist
haracteristic
United Kingdom
(n  619)
emographic and clinical variables
Age (y)
Mean  SD 62  9.0
Median 63.9*
Patients aged  70 y, n (%) 141 (22.8)*
Weight (kg)
Mean  SD 81.4  13.5
Median 80.1
Body mass index  30 kg/m2, n (%) 165 (26.8)
Female sex, n (%) 104 (16.8)
African American or American Indian
or Hispanic ethnic group, n (%)
1 (0.2)
edical history
Diabetes, n (%) 104 (16.8)*
History of smoking,† n (%) 494 (80.1)*
Current smoking, n (%) 49 (7.9)
Unstable angina, n (%) 265 (43.9)
MI, n (%) 357 (58.0)
CHF, n (%) 270 (43.7)
PTCA, n (%) 44 (7.1)*
CABG, n (%) 23 (3.7)
reoperative diagnostic test results
Ejection fraction  44%, n (%) 107 (20.5)
Coronary disease location
Left main, n (%) 162 (26.6)*
Left anterior descending, n (%) 593 (96.3)
Circumflex, n (%) 559 (90.9)
Right, n (%) 570 (92.5)
edications at admission, n (%)
ACE inhibitors 161 (26.0)*
Beta-blockers 412 (66.6)
Calcium channel blockers 352 (56.9)*
Platelet inhibitors 211 (34.1)*
CE, Angiotensin-converting enzyme; CABG, coronary artery bypass graft
ransluminal coronary angiography; SD, standard deviation. *Country w
haracteristic, by pairwise comparisons. †Smoking is regular smoking ofoungest and least likely to have diabetes, unstable angina, c
244 The Journal of Thoracic and Cardiovascular Surgery ● Maeft main coronary artery disease, and previous coronary
ntervention. Angiotensin-converting enzyme inhibitors
ere used most commonly in Germany and the United
tates, calcium channel blockers were used most commonly
n the United Kingdom and Canada, and antiplatelet medi-
ations were used most commonly in the United States and
anada. On the basis of the EuroSCORE, the United King-
om had the highest proportion of patients in the low-risk
roup, whereas the United States cohort had the highest
roportion in the high-risk group (Figure 1). The differences
mong countries in the overall distribution of the Euro-
CORE were significant (P .001). In addition, the process
f care factors (Table 2) varied considerably among
f the 3180 study patients
Canada
(n  444)
United States
(n  1283)
Germany
(n  834) P value
64  9.9 64  9.9 64  9.0
66.1 65.2 64.3 .001
147 (33.1) 415 (32.4) 262 (31.4) .001
82.0  15 84.9  17.7 79.9  12.0
80.55 83.0 79.5 .001
151 (34.0) 569 (44.5)* 179 (21.6) .001
88 (19.8) 239 (18.6) 170 (20.4) .350
11 (2.5)* 183 (14.3)* 0 (0.0) .001
138 (31.2) 478 (37.3) 228 (27.4) .001
310 (69.8) 922 (72.1) 594 (71.3) .001
51 (11.5) 201 (15.7)* 89 (10.7) .001
259 (60.5)* 787 (68.1)* 364 (49.8) .001
270 (60.8) 625 (49.2)* 428 (51.9) .001
71 (16.0)* 348 (27.4) 286 (34.7) .001
91 (20.5) 263 (20.6) 147 (17.7) .001
31 (7.0) 122 (9.5)* 34 (4.1) .001
77 (19.9) 304 (27.6)* 123 (15.9) .001
166 (37.8) 555 (44.5) 300 (36.3) .001
426 (96.2) 1229 (97.3) 800 (96.0) .362
386 (87.1) 1130 (90.3) 757 (90.8) .151
398 (90.5) 1158 (92.1) 756 (90.8) .446
162 (36.5) 494 (38.5) 448 (53.7) .001
337 (75.9)* 793 (61.8) 550 (65.9) .001
186 (41.9)* 326 (25.4) 205 (24.6) .001
296 (66.7) 892 (69.5) 278 (33.3)* .001
, congestive heart failure; MI, myocardial infarction; PTCA, percutaneous
tistically different prevalence (P  .01 with Bonferroni adjustment) in
ttes, cigars, or pipe.ics o
; CHF
ith staountries.
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A
CDetween-country Differences in Outcome
or mortality, unadjusted rates differed among countries
Table 3), but these differences did not survive multivariate
ogistic regression. For morbidity, we found significant dif-
erences among countries in cardiac, cerebral, and renal
orbidity—but not gastrointestinal morbidity—as well as
n overall composite outcome (Table 4). Multivariate logis-
ic regression further demonstrated that the between-country
ifferences in individual organ morbidities and composite
orbidity remained significant.
ultivariate Analysis of Composite Outcome (Within
nd After 48 Hours After Surgery)
one of the individual admission/preoperative risk factors
xplained the inter-country differences in the risk of the
omposite outcome. Among intraoperative factors, admin-
stration of platelets (odds ratio  1.6, 95% confidence
nterval: 1.0-2.3, P  .03) and fresh-frozen plasma (odds
atio  1.5, confidence interval: 1.0-2.2, P  .03) were
ndependently associated with the risk of the composite
utcome, but neither of these eliminated the independent
ffect of country on composite outcome (Table 4). None of
he process of care factors (Table 2) were independently
ssociated with the composite outcome.
arly Outcomes (Within 48 Hours)
here were 338 patients with adverse events within 48
ours after surgery. After adjustment for significant con-
igure 1. Comparison of EuroSCORE among 4 study countries. The
istribution of the EuroSCORE (in low, medium, and high-risk
roups) among 4 countries: United Kingdom, Canada, United
tates, and Germany. Data given in percentages. EuroSCORE,
uropean System for Cardiac Operative Risk Evaluation.ounders (admission, preoperative, and intraoperative fac- a
The Journal of Thoracicors, including the EuroSCORE), country no longer had an
ndependent effect on the risk of the composite outcome
ithin 48 hours. Reversible risk factors for early composite
utcome were the use of aprotinin and transfusion of fresh-
rozen plasma (Table 5, Figure 2).
Aprotinin use was most prevalent in Germany (69%),
ompared with 23% in the United Kingdom, 20% in the
nited States, and only 6% in Canada. The risk of the
omposite outcome (within 48 hours of surgery) was 13.5%
n those treated with aprotinin versus 9.3% (P  .001) for
hose who did not receive aprotinin. The administration of
resh-frozen plasma during surgery was most prevalent in
ermany (11%), followed by the United States (8%), the
nited Kingdom (2%), and Canada (1%). Use of fresh-
rozen plasma was associated with more than a doubling of
he risk of the composite outcome in this period (24.9% vs
.6%, P  .001). None of the process of care factors was
ndependently associated with the early composite outcome.
latelets were used during surgery most frequently in the
nited States (12%), followed by Germany (4%), the
nited Kingdom (1.5%), and Canada (0.75%), but the ad-
inistration of platelets during surgery was not associated
ith the risk of early adverse outcomes.
ate Outcomes (After 48 Hours)
atients with early composite outcomes were excluded in
nalyses of the factors associated with the risk of late compos-
te outcome. Early postoperative use (within 48 hours) of
spirin was associated with a reduced risk of late outcomes,
hereas use of intravenous heparin increased the risk (Table
 ) . The use of aspirin was most prevalent in Canada (83%),
ollowed by the United Kingdom (70%), the United States (67%),
nd Germany (42%) (Figure 3). The administration of heparin
as most prevalent in Germany (75%), followed by Canada
40%), the United Kingdom (17%), and the United States (15%).
esource Use
ime on the waiting list for surgery differed significantly
mong countries, with the United Kingdom showing the
ongest time on the wait list (207 days), followed by Canada
37 days), Germany (21 days), and the United States (6
ays) (Table 2). These findings were consistent across
uroSCORE risk groups. For all countries, higher risk
roups (vs lower risk groups) were associated with shorter
ait time. However, time on the wait list did not account for
uroSCORE differences.
There were significant inter-country differences in all
ntraoperative and postoperative time-related factors (Table 2).
he United Kingdom had the shortest median bypass and
rossclamp times (71 minutes and 38 minutes, respec-
ively) in contrast with the United States (104 minutes
nd 69 minutes, respectively) and Germany (98 minutes
nd 58 minutes, respectively). After correction for the
and Cardiovascular Surgery ● Volume 133, Number 5 1245
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A
CDumber of bypass grafts, these times remained longer in
he United States and Germany than in the United King-
om or Canada.
iscussion
e compared serious adverse vascular outcomes among 4
ountries and attempted to associate the practice patterns of
ach of those countries with those outcomes. Among the
nited States, German, United Kingdom, and Canadian
enters, we found significant differences in outcomes and
rocesses of care, most notably approaches to hemostasis.
ractices that were associated with adverse outcomes in-
luded the intraoperative use of aprotinin and transfusion of
resh-frozen plasma or platelets, and the use of heparin or
ack of administration of aspirin during the early postoper-
tive period. Understanding the mechanisms for these ob-
ervations and the selection of practices associated with
mproved outcomes may result in significant patient benefit.
Transfusion practices for red blood cells and blood prod-
cts have been reported to vary widely between institutions
ABLE 2. Resource use and timelines
esource use
Un
imelines (median)
Time on wait list (d) overall
EuroSCORE 0-3 (low risk)
EuroSCORE 4-7 (medium risk)
EuroSCORE  8 (high risk)
Time preoperatively (h)
Time of anesthesia (min)
Time in OR (min)
Time on CPB (min)
Time of crossclamp (min)
Time ICU stay (h)
Time ICU discharge to hospital discharge (d)
ntraoperative blood products transfusion
Transfusion of platelets in OR, n (%)
Number of units, mean (SD); median 1
Transfusion of RBC in OR, n (%) 11
No. of units, mean (SD); median 1
Transfusion fresh-frozen plasma in OR, n (%) 1
No. of units, mean (SD); median 1
lood loss within 24 h postsurgery (mL), mean (SD); median 76
protinin used in OR, n (%) 14
Return to OR, n (%) 3
edication within 48 h postsurgery, n (%)
Aspirin 43
Heparin 10
PB, Cardiopulmonary bypass; ICU, intensive care unit; EuroSCORE, Europe
lood cell; SD, standard deviation. All data are given as median. Time p
dmission. *Country with statistically different prevalence (P  .01 with Bo
tatistically different prevalence in characteristic (* vs † are also statisticnd countries,20-22 ranging from 0% to 97% for fresh-frozen i
246 The Journal of Thoracic and Cardiovascular Surgery ● Malasma. Prophylactic plasma administration has not been
hown to reduce red cell transfusion,23-29 and recent studies
ave reported an independent risk of stroke and death after
latelet or plasma transfusions.20,30 The association be-
ween blood product transfusion, aprotinin use, or aspirin
dministration and adverse outcome in our study suggests
hat the complex interaction of factors affecting blood
oagulation and hemostasis may play an important role in
linical outcome.
We found that the use of aprotinin and fresh-frozen
lasma was more prevalent among German centers, despite
elatively little difference in blood loss compared with the
ther 3 countries studied. It is possible that frozen plasma
dministration, in combination with aprotinin, may have
onferred additional risk. Although the large majority of
andomized studies comparing aprotinin with placebo or
ther antifibrinolytic agents have not suggested additional
isk with aprotinin, 6 recent investigations reported that the
se of aprotinin is associated with increased adverse out-
omes.31-36 Therefore, our findings raise questions regard-
ingdom
619)
Canada
(n  444)
United States
(n  1283)
Germany
(n  834) P value
.5 37.0 6.0 21.0 .001
37 7 23 .001
46 6 19 .001
36 3 18 .001
.5 23.9 25.8 95.6 .001
.0 226.0 314.0 293.0 .001
.0 170.0 246.0 213.0 .001
.0 72.5 104.0 98.0 .001
.0 44.0 69.0 58.0 .001
.3 26.5 32.5 39.8 .001
.0 4.0 4.0 8.0 .001
)* 3 (0.7)* 151 (11.8) 33 (4.0) .001
); 1 6.3 (1.5); 6 6.9 (5.9); 6 4.6 (2.4); 5
.2) 71 (16.0) 515 (40.2)* 397 (47.6)* .001
); 1 1.8 (1.3); 2 2.5 (1.7); 2 2.8 (2.3); 2
)* 6 (1.4)* 108 (8.4) 88 (10.6) .001
); 2 3.0 (1.1); 3 3.3 (3.0); 2 3.3 (1.6); 3
8); 630 697 (524); 600* 782 (621); 640 823 (677); 680 .001
.1) 25 (5.7)* 250 (19.5) 578 (69.3)† .001
) 23 (5.2) 69 (5.4) 68 (8.2) .021
.3) 369 (83.1) 863 (67.3) 346 (41.5)* .001
.1) 179 (40.3) 198 (15.4) 622 (74.6)* .001
stem for Cardiac Operative Risk Evaluation; OR, operating room; RBC, red
ratively (h) denotes hours from admission to hospital to operating room
oni adjustment) in characteristic, by pairwise comparisons. †Country with
ifferent).ited K
(n 
206
221
196
74
22
219
170
71
38
21
5
9 (1.5
.1 (0.6
9 (19
.6 (0.8
5 (2.4
.9 (0.3
5 (59
3 (23
0 (4.9
5 (70
6 (17
an Sy
reope
nferrng the optimal hematologic management of patients who
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A
CDndergo CABG in general and the coincident use of apro-
inin with frozen plasma, platelets, or other prothrombotic
gents.
Geographic variability has been reported to exist for cost,
ength of stay, volume, and access to and adverse events
fter CABG surgery,35,37,38 although no previous studies
ABLE 3. Between-country differences in outcome
utcome variable, n (%)
United Kingdom
(n  619)
n-hospital mortality (overall) 9 (1.5)‡
EuroSCORE 0-3 (low risk) 2/363 (0.6)
EuroSCORE 4-7 (medium risk) 3/232 (1.3)
EuroSCORE  8 (high risk) 4/24 (16.7)
onfatal morbidity 68 (11.0)‡
orbidity and/or mortality* 77 (12.4)‡
ostoperative cardiac morbidity
MI 42 (6.8)
CHF 21 (3.4)†
ostoperative cerebral morbidity
Encephalopathy 1 (0.2)†
Stroke 11 (1.8)
ostoperative renal morbidity
Renal failure 4 (0.6)
Renal dysfunction 12 (1.9)†
ostoperative gastrointestinal morbidity
GI ischemia/infarction 4 (0.6)
HF, Congestive heart failure; EuroSCORE, European System for Cardia
Composite outcome. †Country with statistically different incidence (P
Statistically different incidence (P  .01 with Bonferroni adjustment) in
onfounders, country no longer had an independent effect on the risk of
ABLE 4. Multivariate analysis for composite outcome: Ad
ariable
y country
Germany vs United Kingdom
United States vs United Kingdom
Canada vs United Kingdom
United Kingdom (reference group)
y patient
EuroSCORE risk group
Low risk (0-3)
Medium risk (4-7)
High risk (8)
Warfarin/Coumadin use within 1 wk before revascularization
Heart failure at admission
Renal disease history
Creatinine  1.3 mg/dL on admission
y practice
Transfusion of fresh-frozen plasma, intraoperative
Transfusion of platelets, intraoperative
I, Confidence interval; OR, odds ratio; EuroSCORE, European System for Ca
ingdom  reference group.)
The Journal of Thoracicave prospectively evaluated the processes of care and
utcomes in the range of countries examined in this inves-
igation. Peterson and colleagues39 found that the hospital at
hich CABG surgery was performed was the strongest
redictor of prolonged stay, although there was also limited
orrelation between mortality and other outcomes.
Canada
(n  444)
United States
(n  1283)
Germany
(n  834) P value
9 (2.0) 34 (2.7) 32 (3.8) .034
0/219 3/547 (0.6) 4/400 (1.0) .539
/182 (2.8) 11/514 (2.1) 12/332 (3.6) .328
4/43 (9.3) 20/222 (9.0) 16/102 (15.7) .245
60 (13.5) 196 (15.3) 167 (20.0) .001
69 (15.5) 231 (18.0) 199 (23.9) .001
14 (3.2)† 86 (6.7) 93 (11.2) .001
43 (9.7) 96 (7.5) 88 (10.6) .001
5 (1.1) 16 (1.2) 24 (2.9) .001
10 (2.3) 25 (2.0) 17 (2.0) .956
4 (0.9) 21 (1.6) 39 (4.7)† .001
10 (2.3)† 49 (3.8) 36 (4.3) .034
0 (0.0) 3 (0.2) 4 (0.5) .257
erative Risk Evaluation; GI, gastrointestinal; MI, myocardial infarction.
1 with Bonferroni adjustment) in outcome, by pairwise comparisons.
me only comparing United Kingdom and Germany. After adjustment for
omposite outcome within 48 hours.
ion, preoperative, and intraoperative risk factors
ence of composite outcome in subgroup
No./total (%)
Adjusted OR
(95% CI) P value
199/834 (23.9) 1.92 (1.42-2.60) .001
231/1283 (18.0) 1.09 (0.81-1.46) .585
69/444 (15.5) 1.21 (0.84-1.74) .306
77/619 (12.4) 1.00
193/1529 (12.6) 1.55 (1.34-1.79) .001
241/1260 (19.1)
142/391 (36.3)
60/198 (30.3) 1.73 (1.23-2.43) .002
175/633 (27.7) 1.60 (1.28-2.01) .001
145/511 (28.4) 1.30 (1.00-1.69) .047
131/454 (28.9) 1.54 (1.17-2.02) .002
79/217 (36.4) 1.52 (1.03-2.25) .034
66/196 (33.7) 1.56 (1.03-2.37) .035
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A
CDThe waiting list time may impact outcome in that a
ountry with a longer list time (eg, the United Kingdom)
ay effectively exclude sicker patients. On the other hand,
onger wait times also have been shown to result in clinical
eterioration, which could then predispose to worse out-
omes in those patients waiting longer.40 However, we
ound no substantial differences among the countries
egarding acute or chronic disease severity at the time of
Figure 2. Factors explaining country differences in
Incidence of composite outcome within 48 hours postsu
transfusion (C and D). Use of risk factors within each
ABLE 5. Multivariate analysis for composite outcome
ntraoperative risk factors
ariable
Incidenc
y patient
EuroSCORE risk group
Low risk (0-3)
Medium risk (4-7)
High risk (8)
Prior hospitalization for CHF
Creatinine  1.3 mg/dL on admission
y practice
Preoperative ACE inhibitors
Preoperative hypoglycemics
Aprotinin use intraoperatively
Transfusion of fresh-frozen plasma intraoperatively
CE, Angiotensin-converting enzyme; CHF, congestive heart failure; CI, c
perative Risk Evaluation.Germany. Data given in percentages. FFP, Fresh-frozen plas
248 The Journal of Thoracic and Cardiovascular Surgery ● Maurgery, suggesting that if wait time did play a role, its
ffects may have been mitigated.
This study has some limitations. The patient selection
rocedures may not be representative of the countries stud-
ed, although the average volume of cardiac cases in centers
hat participated in EPI-II exceeded 1200 patients per year.
e chose the EuroSCORE for risk adjustment because it is
n established index using data from European patients.
y composite outcome within 48 hours postsurgery.
by use of aprotinin (A and B) and fresh-frozen plasma
country: United Kingdom, Canada, United States, and
in 48 hours postsurgery: Admission, preoperative, and
arly composite outcome in subgroup,
No./total (%) OR (95% CI) P value
114/1529 (7.5) 1.566 (1.32-1.84) .001
132/1260 (10.5)
92/391 (23.5)
58/254 (22.8) 1.72 (1.22-2.42) .002
81/454 (17.8) 1.53 (1.15-2.05) .004
173/1210 (14.3) 1.38 (1.09-1.76) .008
95/628 (15.1) 1.37 (1.04-1.79) .023
135/996 (13.6) 1.36 (1.07-1.73) .013
54/217 (24.9) 2.03 (1.43-2.90) .001
ence interval; OR, odds ratio; EuroSCORE, European System for Cardiacearl
rgery
studywith
e of e
onfidma; OR, operating room.
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A
CDlthough some studies have suggested that the EuroSCORE
an accurately predict short and long-term outcomes in
orth American patients, it is possible that it is less accurate
n our non-European cohort. There may have been changes
n the frequency of CABG surgery or the use of alternative
echniques since completion of study enrollment, but the
ack of major changes in the management of patients un-
ergoing CABG with cardiopulmonary bypass makes our
ata current and applicable to this population. Finally, despite
rospective data collection, it is possible that unmeasured
Figure 3. Factors explaining country differences in la
composite outcome 48 hours postsurgery by early use (w
(C and D). Use of risk factors within each study country:
ABLE 6. Multivariate analysis for composite outcome 48 h
ostoperative (within 48 hours) risk factors
ariable
Inciden
y patient
EuroSCORE risk group
Low risk (0-3)
Medium risk (4-7)
High risk (8)
Heart failure on admission
y practice
Aspirin use within 48 h postsurgery
Heparin use within 48 h postsurgery
Transfusion of fresh-frozen plasma intraoperatively
or within 24 h postsurgery
I, Confidence interval; OR, odds ratio; EuroSCORE, European System forgiven in percentages.
The Journal of Thoraciconfounders may exist that could have affected either the risk
djustment or the strength of the outcome associations.
onclusions
e found significant between-country differences in ad-
erse vascular outcomes, as well as processes of care, in
atients who underwent CABG surgery. In particular, the
se of blood products, antifibrinolytics, and antithrombotic
gents differed significantly and appeared to be significantly
ssociated with the differences in outcome. Clearly, causal-
mposite outcome 48 hours postsurgery. Incidence of
48 hours postsurgery) of aspirin (A and B) and heparin
ed Kingdom, Canada, United States, and Germany. Data
postsurgery: Admission, preoperative, intraoperative, and
late composite outcome in subgroup,
No./total (%) OR (95% CI) P value
79/1415 (5.6) 1.54 (1.25-1.88) .001
109/1128 (9.7)
50/299 (16.7)
69/527 (13.1) 1.60 (1.16-2.21) .004
114/1853 (6.2) 0.56 (0.42-0.73) .001
102/975 (10.5) 1.51 (1.14-2.00) .004
71/467 (16.4) 1.95 (1.42-2.67) .001
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A
CDty cannot be invoked; however, among those countries that
ore commonly used early aspirin therapy and avoided
lood product transfusion and use of aprotinin, outcomes
ere improved. Therefore, we surmise that hematologic
ractice plays a critical role in determining the frequency of
dverse outcomes after CABG surgery.
Our appreciation to Brenda Xavier, business manager for the
ulticenter Study of Perioperative Ischemia Research Group, and
iane Beatty, administrative assistant at The Ischemia Research
nd Education Foundation, for their efforts in bringing this article
hrough the various editorial stages.
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